Clinical Trial Detail

NCT ID NCT03047213
Title Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

transitional cell carcinoma

Therapies

Sapanisertib

Age Groups: adult senior

Additional content available in CKB BOOST